Online inquiry

IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1975MR)

This product GTTS-WQ1975MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets SLITRK6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_032229.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84189
UniProt ID Q9H5Y7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1975MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8849MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ11687MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ15237MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TAK-079
GTTS-WQ8459MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ15905MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA XOMA 052
GTTS-WQ14316MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG7414
GTTS-WQ9718MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ9399MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Iomab-B
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW